PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05536440
- Locations
- ๐บ๐ธ
Clinilabs, Eatontown, New Jersey, United States
๐บ๐ธICON, Salt Lake City, Utah, United States
๐บ๐ธOrange County Research Center, Tustin, California, United States
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
- Conditions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT05534789
- Locations
- ๐บ๐ธ
Pfizer New York, New York, New York, United States
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT05525910
- Locations
- ๐บ๐ธ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- Conditions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05522556
Enzalutamide vs. Abiraterone in Chemotherapy-naรฏve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5506
- Registration Number
- NCT05520138
- Locations
- ๐บ๐ธ
Pfizer Inc, New York, New York, United States
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05518123
- Locations
- ๐ช๐ธ
Hospital Universitario Ruber Juan Bravo, Salamanca, Madrid, Spain
๐บ๐ธClinical Research Institute, Los Angeles, California, United States
๐บ๐ธCalifornia Neuroscience Research, LLC, Sherman Oaks, California, United States
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 401
- Registration Number
- NCT05512819
- Locations
- ๐ฎ๐ณ
BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore, Karnataka, India
๐จ๐ณHsinchu Mackay Memorial Hospital, Hsinchu City, Hsinchu, Taiwan
๐ฎ๐ณInstitute of Child Health, Kolkata, WEST Bengal, India
Korean Post-marketing Surveillance Ngenlaยฎ Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 565
- Registration Number
- NCT05509894
- Locations
- ๐ฐ๐ท
Pfizer, Seoul, Korea, Republic of
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05509400
- Locations
- ๐ช๐ธ
Hospital Universitario Ruber Juan Bravo, Salamanca, Madrid, Spain
๐บ๐ธClinical Research Institute, Los Angeles, California, United States
๐บ๐ธKi Health Partners LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05510245
- Locations
- ๐บ๐ธ
Genesis Clinical Research, LLC, Tampa, Florida, United States
๐บ๐ธPrism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States